Mr Mrs Miss Ms Dr Other

Dr
Claire
Green

Trainee Patent Attorney

Glasgow Office

Life sciences

Telephone. +44(0) 141 229 5800
Email. clgreen@hgf.com
Vcard

Experience

Claire specialises in patent protection for bioinformatics, computational biology, and artificial intelligence (AI) inventions. She has extensive experience drafting and prosecuting patent applications related to computational methodologies in areas such as cancer diagnosis, drug design and DNA sequencing. Claire possesses deep technical expertise in AI, genomics, neurotechnology and computational biology.

Claire holds a first-class degree in Neuroscience, an MSc in Clinical Statistics, and a PhD in Computational Biology from the University of Edinburgh. During her doctoral research, she developed and trained predictive models to investigate the impact of epigenetic markers of inflammation on structural neuroimaging phenotypes. She has authored and co-authored several publications in the field of bioinformatics, computational biology, genetics and neuroimaging.

Specialisms

Industries

Services

Qualifications

Trainee

BSC

Neuroscience, University of Glasgow, First Class Honours

MSC

Psychological Science, University of Glasgow, Distinction

PHD

Precision Medicine, University of Edinburgh, Pass with No Corrections

POSTGRADUATE DIPLOMA OR CERTIFICATE

PGCert Intellectual Property Law, University of Bournemouth

Related News

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Unlocking the Soil Microbiome: Driving Agritech Innovation in the UK

The UK offers an ideal platform for harnessing the untapped potential of soil and plant microorganisms. Although much of my professional experience has focused on the human microbiome, I have …

Read article

The Antibody Series #2 | Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us